Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...
Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...
Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...
EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...